Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

OccuLogix

Status and phase: Unknown; Phase 3

Conditions: Macular Degeneration

Treatments: Device: Rheopheresis blood filtration

Study type: Interventional

Funder types: Industry

Identifiers

NCT00078221

AMD-02-99

Details and patient eligibility

About

AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.

Sex: All

Ages: 50 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

• Age 50-85
• Diagnosis of Dry AMD
• BCVA between 20/32 and 20/125 in at least one eye
• Numerous large plaques (soft drusen)
• No history of HIV, Hepatitis B or C
• Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind